GENE ONLINE|News &
Three Companies Received Orphan Drug Designations in One Day To Treat Rare Cancers
The FDA posted three new Orphan Drug Designations (ODD) on June 17 for two companies targeting brain cancer, Kazia and VBI, and one company targeting a type of liver cancer, Hepion. An orphan drug is a treatment targeting a disease that affects less than 200,000 people in the United States. All three companies will use the ODD and the associated benefits to further the development of their drugs targeting rare cancers.
It's free! Log in now to read
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
